"They say GLP-1s for weight loss is a shortcut
Based on a retrospective study of self-reported data of pounds lost for active versus passive users who were offered the Noom program when being prescribed an early stage GLP-1
[1] [3] It is essential to understand that retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) , which is the body responsible for licensing medicines for use in the UK following the UK's departure from the European Union
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: a replication study using reports to the World Health Organization pharmacovigilance database (VigiBase)
GLP-1 RAs are being studied [archived link] for use in many other medical conditions, including fatty liver disease, Parkinsons disease, and substance use disorders, among others
However, what we know so far is that the greatest utilization of these therapies have been observed in predominantly wealthy communities, which have comparatively lower rates of obesity and associated cardiometabolic conditions. Most of the data on these therapies thus far has been driven by clinical trials, which do not account for disruptions in medication adherence that often occur among everyday people
